Pancreatic Cancer Clinical Trial
Official title:
The Prediction Using Diffusion-weighted MRI of the Response Evaluation in Borderline Resectable Pancreatic Cancer.
To investigate the correlation between pretreatment ADC value of diffusion MRI and pathologic response in patients with borderline resectable pancreatic carcinoma who undergo neoadjuvant therapy.
Aim: The prediction using diffusion-weighted MRI of the response evaluation in borderline
resectable pancreatic cancer.
Study design: Single institution. Single arm. Prospective Phase II Study.
Number of case: 28
Patients: The prediction using dMRI of the response evaluation in borderline resectable
pancreatic carcinoma (BRPC) in neoadjuvant therapy.
Disease: Pancreatic carcinoma
Method: To investigate the correlation between pretreatment ADC value of diffusion MRI and
pathologic response in patients with borderline resectable pancreatic carcinoma who undergo
neoadjuvant therapy.
The correlation between pretreatment ADC value of diffusion MRI and pathologic response
evaluated by Evans grade in patients with borderline resectable pancreatic carcinoma (BRPC)
who undergo neoadjuvant therapy.
1. The correlation between pretreatment ADC value at the abutment site of BRPC and the rate
of tumor cell destruction.
2. The correlation between posttreatment ADC value at the abutment site of BRPC and the
rate of tumor cell destruction.
3. The correlation between the ratio of posttreatment/pretreatment ADC value at the
abutment site of BRPC and the rate of tumor cell destruction.
4. The correlation between pretreatment ADC value of BRPC tumor in a largest diameter and
the rate of tumor cell destruction.
5. The correlation between the ratio of posttreatment/pretreatment ADC value of BRPC tumor
in a largest diameter and the rate of tumor cell destruction.
6. ADC Cut-off value which predict more than 50% and less than 10% in tumor cell
destruction rate.
7. The correlation between the ratio of posttreatment/pretreatment ADC value of BRPC tumor
in a largest diameter and the ratio of posttreatment/pretreatment SUV max.
8. ADC Cut-off value and SUV max cut-off value which predict survival time after surgery
more than 2 years and less than 2 years.
9. The comparison of the accuracy of prediction for pathological diagnosis at abutment site
between the ratio of posttreatment/pretreatment ADC value and CT scan.
10. Three correlation between high ADC value/low ADC value/the ratio of
posttreatment/pretreatment ADC value and survival time after surgery.
11. Three correlation between high ADC value/low ADC value/the ratio of
posttreatment/pretreatment ADC value and decreasing rate of CA19-9 value.
12. The correlation between tumor's limb sign in diffusion MRI and the rate of tumor cell
destruction more than 10%.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
| Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|